346 related articles for article (PubMed ID: 31941438)
1. Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model.
Lukkes JL; Drozd HP; Fitz SD; Molosh AI; Clapp DW; Shekhar A
J Neurodev Disord; 2020 Jan; 12(1):2. PubMed ID: 31941438
[TBL] [Abstract][Full Text] [Related]
2. The behavioural response of mice lacking NK₁ receptors to guanfacine resembles its clinical profile in treatment of ADHD.
Pillidge K; Porter AJ; Dudley JA; Tsai YC; Heal DJ; Stanford SC
Br J Pharmacol; 2014 Oct; 171(20):4785-96. PubMed ID: 25074741
[TBL] [Abstract][Full Text] [Related]
3. Systemic administration of guanfacine improves food-motivated impulsive choice behavior primarily via direct stimulation of postsynaptic α
Nishitomi K; Yano K; Kobayashi M; Jino K; Kano T; Horiguchi N; Shinohara S; Hasegawa M
Behav Brain Res; 2018 Jun; 345():21-29. PubMed ID: 29476896
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiological and Clinical Predictors of Methylphenidate, Guanfacine, and Combined Treatment Outcomes in Children With Attention-Deficit/Hyperactivity Disorder.
Michelini G; Lenartowicz A; Vera JD; Bilder RM; McGough JJ; McCracken JT; Loo SK
J Am Acad Child Adolesc Psychiatry; 2023 Apr; 62(4):415-426. PubMed ID: 35963559
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder.
Sallee FR; Kollins SH; Wigal TL
J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):206-14. PubMed ID: 22612526
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of postsynapse adrenergic α2A receptor improves attention/cognition performance in an animal model of attention deficit hyperactivity disorder.
Kawaura K; Karasawa J; Chaki S; Hikichi H
Behav Brain Res; 2014 Aug; 270():349-56. PubMed ID: 24882610
[TBL] [Abstract][Full Text] [Related]
7. Effects of α-2A adrenergic receptor agonist on time and risk preference in primates.
Kim S; Bobeica I; Gamo NJ; Arnsten AF; Lee D
Psychopharmacology (Berl); 2012 Jan; 219(2):363-75. PubMed ID: 21979441
[TBL] [Abstract][Full Text] [Related]
8. Guanfacine extended-release: in attention deficit hyperactivity disorder.
Muir VJ; Perry CM
Drugs; 2010 Sep; 70(13):1693-702. PubMed ID: 20731476
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd).
Alamo C; López-Muñoz F; Sánchez-García J
Actas Esp Psiquiatr; 2016 May; 44(3):107-12. PubMed ID: 27254403
[TBL] [Abstract][Full Text] [Related]
10. Noradrenergic α2A-receptor stimulation in the ventral hippocampus reduces impulsive decision-making.
Abela AR; Chudasama Y
Psychopharmacology (Berl); 2014 Feb; 231(3):521-31. PubMed ID: 24062084
[TBL] [Abstract][Full Text] [Related]
11. Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
Rizzo R; Martino D
Expert Rev Neurother; 2015 Apr; 15(4):347-54. PubMed ID: 25800130
[TBL] [Abstract][Full Text] [Related]
12. Juvenile exposure to methylphenidate and guanfacine in rats: effects on early delay discounting and later cocaine-taking behavior.
Freund N; Jordan CJ; Lukkes JL; Norman KJ; Andersen SL
Psychopharmacology (Berl); 2019 Feb; 236(2):685-698. PubMed ID: 30411140
[TBL] [Abstract][Full Text] [Related]
13. Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy.
Ota T; Yamamuro K; Okazaki K; Kishimoto T
Drug Des Devel Ther; 2021; 15():1965-1969. PubMed ID: 34007156
[TBL] [Abstract][Full Text] [Related]
14. Alpha 2A adrenergic receptor agonist, guanfacine, attenuates cocaine-related impairments of inhibitory response control and working memory in animal models.
Terry AV; Callahan PM; Schade R; Kille NJ; Plagenhoef M
Pharmacol Biochem Behav; 2014 Nov; 126():63-72. PubMed ID: 25242808
[TBL] [Abstract][Full Text] [Related]
15. Effects of d-Methylphenidate, Guanfacine, and Their Combination on Electroencephalogram Resting State Spectral Power in Attention-Deficit/Hyperactivity Disorder.
Loo SK; Bilder RM; Cho AL; Sturm A; Cowen J; Walshaw P; Levitt J; Del'Homme M; Piacentini J; McGough JJ; McCracken JT
J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):674-682.e1. PubMed ID: 27453081
[TBL] [Abstract][Full Text] [Related]
16. Noradrenergic contributions to cue-driven risk-taking and impulsivity.
Chernoff CS; Hynes TJ; Winstanley CA
Psychopharmacology (Berl); 2021 Jul; 238(7):1765-1779. PubMed ID: 33649970
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
[TBL] [Abstract][Full Text] [Related]
18. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents.
Connor DF; Rubin J
Drugs Today (Barc); 2010 May; 46(5):299-314. PubMed ID: 20517532
[TBL] [Abstract][Full Text] [Related]
19. Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder.
Bilder RM; Loo SK; McGough JJ; Whelan F; Hellemann G; Sugar C; Del'Homme M; Sturm A; Cowen J; Hanada G; McCracken JT
J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):667-73. PubMed ID: 27453080
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Pharmacologic Considerations for Guanfacine Use in Very Young Children.
Black BT; Soden SE; Kearns GL; Jones BL
J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):498-504. PubMed ID: 26894823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
